Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   
Assessing the Impact of Childhood Interventions on Subsequent Drug Use Home
Assessing the Impact of Childhood Interventions
on Subsequent Drug Use
skip navigation About the Conference
Agenda
Commissioned Papers
Barbara J. Burns, Ph.D.
Scott N. Compton, Ph.D.
Helen L. Egger, M.D.
Elizabeth M.Z. Farmer, Ph.D.
E. Jane Costello
Tonya D. Armstrong
Alaattin Erkanli
Paul E. Greenbaum
Chi-Ming Kam
Linda M. Collins
Selected Bibliography
Program Contacts

Report on the Developmental Epidemiology of Comorbid Psychiatric and Substance Use Disorders

Costello, Armstrong & Erkanli

Links to other parts of this paper:


Tables

Table 2. Rates of substance abuse/dependence and psychiatric comorbidity in community-based samples (continued)

Study

N

Age

Time frame

Pop rate of
a (%)

Pop rate of
b (%)

Rate of a in
b (%)

Rate of a in not
b (%)

Rate of b in
a (%)

Rate of b in not
a (%)

OR

CI

a=substance abuse/dependence, b=ADHD, in males

1

142

19

12 mo

12.4

              

n/a

  

4

411

14 to 16

lifetime

10.5

5.2

     

12.3

1.8

5.4

0.2, 10.6

5

1420

9 to 16

3 mo

5.7

  

11.3

1.5

     

8.4

5.4, 11.4

6

271

16 to 19

lifetime

12.4, 12.4

              

n/a

  

7

578

17

12 mo

22.8

4.8

14.3

23.3

3

5.4

1.3

0.9, 1.7

8

961

15

6 mo

6.5

5.7

           

7

3.6, 13.7

12

211

14 to 17

6 mo

7.1

13.8

     

68

10.1

20.3

7.6, 33.0

13

698

15 to 19

lifetime

11.75

4.15

28.8

6.7

25.4

5.7

5.6

4.3, 6.9

14

1507

14 to 18

lifetime

9.8

6.2

35.1

  

22.3

  

5.9

4.5, 7.3

15

1507

14 to 18

lifetime

6.2

6.2

     

25.5

2.5

13.9

9.8, 18.0

16

1710

14 to 18

lifetime

8.3

              

n/a

  

18

2181

16 to 17

1 mo

11

              

n/a

  

20

476

18

12 mo

60.7

              

n/a

  

a=substance abuse/dependence, b=ODD, in females

1

142

19

12 mo

12.4

              

n/a

  

4

363

14 to 16

lifetime

10.5

1.6

     

2.5

1.2

2.1

1.0, 6.3

5

1420

9 to 16

3 mo

6.3

  

26.2

1.1

     

31.8

21.7, 41.9

6

271

16 to 19

lifetime

5.9, 7.8

              

n/a

  

7

674

17

12 mo

20.3

              

n/a

  

8

961

15

6 mo

8.9

9.5

           

11.4

8.3, 14.5

12

190

14 to 17

6 mo

5.3

13.8

     

68

10.1

20.3

7.6, 33.0

13

810

15 to 19

lifetime

10

1.6

28.8

6.7

25.4

5.7

5.6

4.3, 6.9

14

1507

14 to 18

lifetime

9.8

6.2

35.1

  

22.3

  

6

4.6, 7.4

15

1507

14 to 18

lifetime

6.2

6.2

     

25.5

2.5

13.9

9.8, 18.0

16

1710

14 to 18

lifetime

8.3

7.3

           

n/a

  

18

2326

12 to 17

1 mo

10.4

21.5

  

4

25.5

  

3.3

2.7, 3.9

20

454

18

12 mo

12.6

              

n/a

  

a=substance abuse/dependence, b=ODD, in males

1

142

19

12 mo

12.4

              

n/a

  

4

411

14 to 16

lifetime

10.5

1.6

     

2.5

1.2

2.1

1.0, 6.3

5

1420

9 to 16

3 mo

5.7

  

11.3

1.5

     

8.4

5.4, 11.4

6

271

16 to 19

lifetime

12.4, 12.4

              

n/a

  

7

578

17

12 mo

22.8

              

n/a

  

8

961

15

6 mo

6.5

12.2

           

11.4

8.3, 14.5

12

211

14 to 17

6 mo

7.1

13.8

     

68

10.1

20.3

7.6, 33.0

13

698

15 to 19

lifetime

11.75

2.58

28.8

6.7

25.4

5.7

5.6

4.3, 6.9

14

1507

14 to 18

lifetime

9.8

6.2

35.1

  

22.3

  

6

4.6, 7.4

15

1507

14 to 18

lifetime

6.2

6.2

     

25.5

2.5

13.9

9.8, 18.0

16

1710

14 to 18

lifetime

8.3

7.3

           

n/a

  

18

2181

16 to 17

1 mo

11

14.4

  

5

26.2

  

4.8

4.0, 5.6

20

476

18

12 mo

60.7

              

n/a

  

a=substance abuse/dependence, b=CD, in females

1

142

19

12 mo

12.4

              

n/a

  

4

363

14 to 16

lifetime

10.5

14.5

     

44.4

0

9.5

  

5

1420

9 to 16

3 mo

6.3

  

26.2

1.1

     

31.9

21.8, 42.0

6

271

16 to 19

lifetime

5.9, 7.8

              

n/a

  

7

674

17

12 mo

20.3

11.9

52.5

16

30.7

7.1

5.8

4.3, 7.3

8

961

15

6 mo

8.9

9.5

           

11.4

8.3, 14.5

12

190

14 to 17

6 mo

5.3

13.8

     

68

10.1

20.3

7.6, 33.0

13

810

15 to 19

lifetime

10

1.6

28.8

6.7

25.4

5.7

5.6

4.3, 6.9

14

1507

14 to 18

lifetime

9.8

6.2

35.1

  

22.3

  

6

4.6, 7.4

15

1507

14 to 18

lifetime

6.2

6.2

     

25.5

2.5

13.9

9.8, 18.0

16

1710

14 to 18

lifetime

8.3

7.3

           

n/a

  

18

2326

12 to 17

1 mo

10.4

21.5

  

4

25.5

  

13.9

9.8, 18.0

20

454

18

12 mo

12.6

2.2

60.8

13

21.4

2.5

10.6

3.6, 17.6

a=substance abuse/dependence, b=CD, in males

1

142

19

12 mo

                 

n/a

  

4

411

14 to 16

lifetime

10.5

14.5

     

44.4

0

9.5

  

5

1420

9 to 16

3 mo

5.7

  

11.3

1.5

     

8.4

5.4, 11.4

6

271

16 to19

lifetime

12.4, 12.4

              

n/a

  

7

578

17

12 mo

22.8

28.5

38.8

16.5

48.5

22.6

4.6

3.6, 5.6

8

961

15

6 mo

6.5

12.2

           

11.4

8.3, 14.5

12

211

14 to 17

6 mo

7.1

13.8

     

68

10.1

20.3

7.6, 33.0

13

698

15 to 19

lifetime

11.75

2.58

28.8

6.7

25.4

5.7

5.6

4.3, 6.9

14

1507

14 to 18

lifetime

9.8

6.2

35.1

  

22.3

  

6

4.6, 7.4

15

1507

14 to 18

lifetime

6.2

6.2

     

25.5

2.5

13.9

9.8, 18.0

16

1710

14 to 18

lifetime

8.3

7.3

           

n/a

  

18

2181

16 to 17

1 mo

11

14.4

  

5

26.2

  

4.8

4.0, 5.6

20

476

18

12 mo

60.7

8.6

60.8

13

21.4

2.5

10.5

6.8, 14.2

Note.

Study 1. Beitchman, Douglas, Wilson, Johnson, Young, Atkinson, Escobar, & Taback, 1999

Study 4. Chong, Chan, & Cheng, 1999

Study 5. Costello, Erkanli, Federman, & Angold, 1999

Study 6. Deykin, Levy, & Wells, 1987

Study 7. Disney, Elkins, McGue, & Iacono, 1999

Study 8. Fergusson, Horwood, & Lynskey, 1993

Study 12. Kandel, Johnson, Bird, Weissman, Goodman, Lahey, Regier, & Schwab-Stone, 1999

Study 13. Lewinsohn, Hops, Roberts, Seeley, & Andrews, 1995

Study 14. Lewinsohn, Rohde, & Seeley, 1995

Study 15. Rohde, Lewinsohn, & Seeley, 1996

Study 16. Rohde, Lewinsohn, & Seeley, 1991

Study 18. Substance Abuse and Mental Health Services Administration, 1999

Study 20. Feehan, McGee, Raja, & Williams, 1994

ADHD = attention-deficit/hyperactivity disorder; CD = conduct disorder; CI = confidence interval; ODD = oppositional defiant disorder; OR = odds ratio


Back to Top

Table 3. Studies that meet minimum criteria for further analysis Revised 4/4/2000

Current PI

Number of
participants

# Waves

Age range of data

Sex ratio

Race/ethnic groups (AA=
African American)

Timing?

Impair-
ment?

Study Title and Comments

1. Terrie Moffitt 1,037 11 birth-26 1:1 93% White
6% Maori
    Dunedin Study. Birth cohort from New Zealand
2. Ron Kessler 479 1 (2nd coming) 15-17 1:1 74% White
15% AA
    From National Comorbidity Survey.
10-year followup
3. Frederick Gibbons 897 2 10-13 1:1 91% AA ?   Family and Community Health Study (offshoot of Rand Conger's IYFP, studying rural AA families)
4. Rand Conger 530 9-11 12-23 1:1 White     Iowa Youth and Families Project. Longitudinal study of rural families
5. Peter Lewinsohn 1,500 3 (interview)

7 (questionnaire)

14-24 1:1 91% White     Oregon Adolescent Depression Project
6.Helen Reinherz 400 7 5-26 1:1 98% White     Youth in Boston
7. David Fergusson 1,200 20 birth-24 1:1 87% White 12% Maori     Christchurch Study. Birth cohort from New Zealand
8. Hector Bird 777 1 4-16 1:1 Puerto Rican ?   Population sample, Puerto Rico

Cross-sectional, no onset data, but wide age range

9. David Huizinga 1,500 5 7-27 1:1 45% Hispanic 34% AA
12% White
  ? (drug use only) Denver Youth Survey

Depression, CD, ASPD only

10. Jane Costello 1,420 6 9-19 1:1 69% White
6% AA

25% American Indian
    Great Smoky Mountains Study. Rural southeastern USA
11. Adrian Angold 921 1-3 9-18 1:1 55% AA
45% White
    Caring for Children in the Community. Rural S-E USA
12. Rolf Loeber 503

15

7-20 Boys 50% AA
50% White
    Pittsburgh Youth Study Focus on development of delinquency
13. Jan Beals 109 1 (2) 14-16 1:1 American Indian ?   Plains Indians study. Followup of 44% of 249 youth studied 6 years earlier.
14. Peter Jensen 1,285  

1

9-17 1:1 52% White
15% AA
28% Hispanic
6% other
    MECA Single wave at four sites including Puerto Rico
15. Peter Jensen W1 500
W2 350
2 9-17 1:1 28% AA
59% White
7% Hispanic
    Fort Meade Study Children on military base. Followup of 70% 1 year later
16. Robert Roberts W1 4,208
W2 3,156
2 11-17 1:1 36% AA
36% White
27% Mexican American
    Teen Health 2000 Random sample from two HMOs. Limited range of comorbid Dxs


Back to Top



Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal